Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > New healthcare company that’s come to my attention is $AGN.c

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Jul 14, 2022 7:03pm

192 Views

Post# 34825566

New healthcare company that’s come to my attention is $AGN.c

New healthcare company that’s come to my attention is $AGN.c , Algeron pharmaceuticals.

https://twitter.com/WolfOfOakville/status/1488897067477090310

U can check out Wolf Of Oakville’s review on them in the link above, $AGN.c had a successful IPO launching to $3.17. $AGN.c is in the pre clinical trial phase for their Reprinast, treatment for chronic kidney disease, still in the early stages of development $AGN.c will continue to conduct studies testing the bio-availability of Reprinast.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project